Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

398.2

$million

Invested

92

innovative

Projects

12

different

Countries

12

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2021-2022

Annual Report

Working Together to Address the Global Threat of Antimicrobial Resistance

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
Wellcome
UK Government
BARDA
NIAID

Alliance Partners

Bill and Melinda Gates Foundation

Events

Events

06.10.23

 

Engaging the Pharmaceutical Industry in Joint Efforts to Tackle ANTIMICROBIAL RESISTANCE

06.12.23

 

Boston Bacterial Meeting 2023

06.15.23

Houston 

ASM Microbe 2023

CARB-X News

  • 04.27.2023  |  CARB-X 2021-22 ANNUAL REPORT LAUNCHED TODAY full release

  • 03.09.2023  |  CARB-X announces appointment of Dan Burgess as Board Chair full release

  • 12.21.2022  |  CARB-X welcomes the G20 call to action on Antimicrobial resistance full release

See All News

In The News

  • 05.15.2023  |  New WHO report highlights progress, but also remaining gaps, in ensuring a robust pipeline of antibiotic treatments to combat antimicrobial resistance (AMR) full story

  • 05.07.2023  |  Towards a reformed R&D ecosystem for infectious disease full story

  • 03.30.2023  |  Rapid Pathogen ID/AST Market Begins to Recover Post-COVID as Drug-Resistant Infections Spike full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.